217 related articles for article (PubMed ID: 30185708)
21. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
Marty C; Pecquet C; Nivarthi H; El-Khoury M; Chachoua I; Tulliez M; Villeval JL; Raslova H; Kralovics R; Constantinescu SN; Plo I; Vainchenker W
Blood; 2016 Mar; 127(10):1317-24. PubMed ID: 26608331
[TBL] [Abstract][Full Text] [Related]
22. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
23. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
24. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
25. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of endogenous thrombopoietin receptor (MPL) with in vivo passage of calreticulin (CALR) mutant Ba/F3 cells, highlighting MPL as the requisite cytokine receptor for CALR mediated transformation.
Brooks SA; Kim DM; Morse SJ; Nguyen QH; Craver BM; Lai HY; Fleischman AG
Leuk Res; 2019 Jul; 82():11-14. PubMed ID: 31128484
[No Abstract] [Full Text] [Related]
28. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.
Di Buduo CA; Abbonante V; Marty C; Moccia F; Rumi E; Pietra D; Soprano PM; Lim D; Cattaneo D; Iurlo A; Gianelli U; Barosi G; Rosti V; Plo I; Cazzola M; Balduini A
Blood; 2020 Jan; 135(2):133-144. PubMed ID: 31697806
[TBL] [Abstract][Full Text] [Related]
29. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
[TBL] [Abstract][Full Text] [Related]
30. Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.
Merlinsky TR; Levine RL; Pronier E
Clin Cancer Res; 2019 May; 25(10):2956-2962. PubMed ID: 30655313
[TBL] [Abstract][Full Text] [Related]
31. [New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS; Hasselbalch HC
Ugeskr Laeger; 2015 May; 177(19):. PubMed ID: 25967091
[TBL] [Abstract][Full Text] [Related]
32. Mutant calreticulin: when a chaperone becomes intrusive.
Cazzola M
Blood; 2016 Mar; 127(10):1219-21. PubMed ID: 26965919
[TBL] [Abstract][Full Text] [Related]
33. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.
Rivera JF; Baral AJ; Nadat F; Boyd G; Smyth R; Patel H; Burman EL; Alameer G; Boxall SA; Jackson BR; Baxter EJ; Laslo P; Green AR; Kent DG; Mullally A; Chen E
Blood Adv; 2021 Apr; 5(7):1922-1932. PubMed ID: 33821991
[TBL] [Abstract][Full Text] [Related]
34. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice.
Toppaldoddi KR; da Costa Cacemiro M; Bluteau O; Panneau-Schmaltz B; Pioch A; Muller D; Villeval JL; Raslova H; Constantinescu SN; Plo I; Vainchenker W; Marty C
Oncogene; 2019 Mar; 38(10):1651-1660. PubMed ID: 30846848
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers.
Venkatesan A; Geng J; Kandarpa M; Wijeyesakere SJ; Bhide A; Talpaz M; Pogozheva ID; Raghavan M
J Cell Biol; 2021 Jul; 220(7):. PubMed ID: 33909030
[TBL] [Abstract][Full Text] [Related]
36. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs.
Jutzi JS; Marneth AE; Ciboddo M; Guerra-Moreno A; Jiménez-Santos MJ; Kosmidou A; Dressman JW; Liang H; Hamel R; Lozano P; Rumi E; Doench JG; Gotlib J; Krishnan A; Elf S; Al-Shahrour F; Mullally A
Blood; 2022 Sep; 140(11):1291-1304. PubMed ID: 35763665
[TBL] [Abstract][Full Text] [Related]
37. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.
Shirane S; Araki M; Morishita S; Edahiro Y; Takei H; Yoo Y; Choi M; Sunami Y; Hironaka Y; Noguchi M; Koike M; Noda N; Ohsaka A; Komatsu N
Haematologica; 2015 Feb; 100(2):e46-8. PubMed ID: 25398833
[No Abstract] [Full Text] [Related]
38. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
[TBL] [Abstract][Full Text] [Related]
39. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit?
Gorbenko AS; Stolyar MA; Olkhovskiy IA; Vasiliev EV; Mikhalev MA
Clin Chem Lab Med; 2019 Mar; 57(4):e60-e62. PubMed ID: 30157024
[No Abstract] [Full Text] [Related]
40. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.
Jia R; Kralovics R
Int J Hematol; 2020 Feb; 111(2):182-191. PubMed ID: 31741139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
